Page last updated: 2024-12-07

procion orange mx-2r

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Procion Orange MX-2R: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

procion orange MX-2R : A 2,4-dichloro-1,3,5-triazine with a multi-substituted napthalen-2-yldiazenyl substituent at the 6-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID93408
CHEBI ID58963
SCHEMBL ID10024206
SCHEMBL ID14431092
MeSH IDM0122769

Synonyms (22)

Synonym
procion orange mx2r
2-(6-(4,6-dichloro-s-triazinyl)methylamino-1-hydroxy-3-sulfonaphthylazo)-1,5-naphthalenedisulfonic acid
2-({6-[(4,6-dichloro-1,3,5-triazin-2-yl)(methyl)amino]-1-hydroxy-3-sulfonaphthalen-2-yl}diazenyl)naphthalene-1,5-disulfonic acid
CHEBI:58963 ,
73816-75-8
einecs 277-617-9
oranz brilantni ostazinova s-2r [czech]
procion orange mx-2r
2-((6-((4,6-dichloro-1,3,5-triazin-2-yl)methylamino)-1-hydroxy-3-sulpho-2-naphthyl)azo)naphthalene-1,5-disulphonic acid
1,5-naphthalenedisulfonic acid, 2-(6-(4,6-dichloro-s-triazinyl)methylamino-1-hydroxy-3-sulfonaphthylazo)-
oranz brilantni ostazinova s-2r
EPITOPE ID:119707
SCHEMBL10024206
SCHEMBL14431092
AKOS024421046
2-((e)-{6-[(4,6-dichloro-1,3,5-triazin-2-yl)(methyl)amino]-1-hydroxy-3-sulfo-2-naphthyl}diazenyl)-1,5-naphthalenedisulfonic acid
Q27126364
2-((6-((4,6-dichloro-1,3,5-triazin-2-yl)(methyl)amino)-1-hydroxy-3-sulfonaphthalen-2-yl)diazenyl)naphthalene-1,5-disulfonic acid
SB73450
2-[[6-[(4,6-dichloro-1,3,5-triazin-2-yl)-methylamino]-1-hydroxy-3-sulfonaphthalen-2-yl]diazenyl]naphthalene-1,5-disulfonic acid
DTXSID40867932
2-((6-((4,6-dichloro-1,3,5-triazin-2-yl)(methyl)amino)-1-hydroxy-3-sulfonaphthalen-2-yl)diazenyl)naphthalene-1,5-disulfonicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
dyenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
chloro-1,3,5-triazineA member of the class of 1,3,5-triazines that is 1,3,5-triazine substituted by at least one chloro group at unspecified position.
monoazo compoundCompounds containing single -N=N- group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's3 (42.86)18.2507
2000's2 (28.57)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]